Injectable HDV-GLP-1, Novel Mechanism

About Diasome Pharmaceuticals

Diasome Pharmaceuticals is a clinical-stage biotech leveraging its HDV™ platform to create liver-targeted therapies for metabolic diseases. Its core technology uses a lipid nanoparticle (bicelle) with a biotin tag to selectively deliver drug actives to hepatocytes, aiming to enhance efficacy and reduce side effects by restoring natural physiological pathways. The most advanced program, OPTI-2 (HDV-Rapid Acting Insulin), is in Phase 2b for Type 1 Diabetes, with preclinical programs in GLP-1 and serotonin-based therapies. As a private company, Diasome is positioned to address significant unmet needs in the large and growing diabetes and obesity markets.

Therapeutic Areas